参考文献/References:
[1] Bartley GB.The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County,Minnesota [J].Trans Am Ophthalmol Soc,1994,92:477-588.
[2] Perros P,Hegedüs L,Bartalena L,et al.Graves' orbitopathy as a rare disease in Europe:a European Group on Graves' Orbitopathy(EUGOGO)position statement[J].Orphanet J Rare Dis,2017,12(1):72.DOI:10.1186/s13023-017-0625-1.
[3] Chin YH,Ng CH,Lee MH,et al.Prevalence of thyroid eye disease in Graves' disease:a meta-analysis and systematic review [J].Clin Endocrinol(Oxf),2020,93(4):363-374.DOI:10.1111/cen.14296.
[4] Stiebel-Kalish H,Robenshtok E,Hasanreisoglu M,et al.Treatment modalities for Graves' ophthalmopathy:systematic review and metaanalysis[J].J Clin Endocrinol Metab,2009,94(8):2708-2716.DOI:10.1210/jc.2009-0376.
[5] Bartalena L,Krassas GE,Wiersinga W,et al.European Group on Graves' Orbitopathy.Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy [J].J Clin Endocrinol Metab,2012,97(12):4454-4463.DOI:10.1210/jc.2012-2389.
[6] Blandford AD,Zhang D,Chundury RV,et al.Dysthyroid optic neuropathy:update on pathogenesis,diagnosis,and management [J].Expert Rev Ophthalmol,2017,12(2):111-121.DOI:10.1080/17469899.2017.1276444.
[7] Schovanek J,Cibickova L,Karhanova M,et al.Retrospective analysis of patients with Graves orbitopathy treated by pulses of methylprednisolong,with a focus on adverse events[J].Endocr Pract,2018,24(7):652-657.DOI:10.4158/EP-2018-0047.
[8] Shen WC,Lee CH,Loh EW,et al.Efficacy and safety of rituximab for the treatment of graves' orbitopathy:a meta-analysis of randomized controlled trials [J].Pharmacotherapy,2018,38(5):503-510.DOI:10.1002/phar.2111.
[9] De Meyts P.Insulin and its receptor:structure,function and evolution [J].Bioessays,2004,26(12):1351-1362.DOI:10.1002/bies.20151.
[10] Pritchard J,Han R,Horst N,et al.Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway [J].J Immunol,2003,170(12):6348-6354.DOI:10.4049/jimmunol.170.12.6348.
[11] Smith T J,Hoa N.Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen,insulin-like growth factor-I receptor [J].J Clin Endocrinol Metab,2004,89(10):5076-5080.DOI:10.1210/jc.2004-0716.
[12] acheta D,Mis'kiewicz P,Guszko A,et al.Immunological aspects of Graves' ophthalmopathy [J].Biomed Res Int,2019,2019:7453260.DOI:10.1155/2019/7453260.
[13] Tsui S,Naik V,Hoa N.Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors:a tale of two antigens implicated in Graves' disease [J].J Immunol,2008,181(6):4397-4405.DOI:10.4049/jimmunol.181.6.4397.
[14] Smith TJ,Hegedüs L.Graves' disease [J].N Engl J Med,2016,375(16):1552-1565.DOI:10.1056/NEJMra1510030.
[15] Marinò M,Rotondo Dottore G,Ionni I,et al.Serum antibodies against the insulin-like growth factor-Ⅰ receptor(IGF-ⅠR)in Gravess' disease and Gravess' ophthalmopathy [J].J Endocrinol Invest,2019,42(4):471-480.DOI:10.1007/s40618-018-0943-8.
[16] Philippou A,Christopoulos PF,Koutsilieris DM.Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer [J].Mutat Res Rev Mutat Res,2017,772:105-122.DOI:10.1016/j.mrrev.2016.09.005.
[17] Smith TJ.Thyroid-associated ophthalmopathy:emergence of teprotumumab as a promising medical therapy [J].Best Pract Res Clin Endocrinol Metab,2020,34(1):101383.DOI:10.1016/j.beem.2020.101383.
[18] Chen H,Mester T,Raychaudhuri N,et al.Teprotumumab,an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes [J].J Clin Endocrinol Metab,2014,99(9):1635-1640.DOI:10.1210/jc.2014-1580.
[19] Chen H,Shan SJ,Mester T,et al.TSH-mediated TNFα production in human fibrocytes is inhibited by teprotumumab,an IGF-1R antagonist [J].PLoS One,2015,10(6):e0130322.DOI:10.1371/journal.pone.0130322.
[20] Smith TJ,Kahaly GJ,Ezra DG,et al.Teprotumumab for thyroid-associated ophthalmopathy [J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[21] Douglas RS,Kahaly GJ,Patel A,et al.Teprotumumab for the treatment of active thyroid eye disease [J].N Engl J Med,2020,382(4):341-352.DOI:10.1056/NEJMoa1910434.
[22] FDA.Approves first treatment for thyroid eye disease[EB/OL].(2020-01-21)[2021-04-20].https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease.
[23] Bartalena L,Kahaly GJ,Baldeschi L,et al.EUGOGO.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[24] Kahaly GJ,Douglas RS,Holt RJ,et al.Teprotumumab for patients with active thyroid eye disease:a pooled data analysis,subgroup analyses,and off-treatment follow-up results from two randomised,double-masked,placebo-controlled,multicentre trials[J].Lancet Diabetes Endocrinol,2021,9(6):360-372.DOI:10.1016/S2213-8587(21)00056-5.
[25] Sears CM,Azad AD,Dosiou C,et al.Teprotumumab for dysthyroid optic neuropathy:early response to therapy [J].Ophthalmic Plast Reconstr Surg,2021,37(3S):S157-S160.DOI:10.1097/IOP.0000000000001831.
[26] Douglas RS,Dailey R,Subramanian PS,et al.Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease:a meta-analysis and matching-adjusted indirect comparison[J].JAMA Ophthalmol,2022,17:e216284.DOI:10.1001/jamaophthalmol.2021.6284.
相似文献/References:
[1]曹雯,郑仁东,陈国芳,等.甲状腺功能亢进症伴严重药物性胆汁郁积性肝炎1例并文献复习[J].国际内分泌代谢杂志,2014,(03):214.[doi:10.3760/cma.j.issn.1673-4157.2014.03.020]
Cao Wen,Zheng Rendong,Chen Guofang,et al.One case of hyperthyroidism with severe drug-induced cholestasis hepatitis and literature review[J].International Journal of Endocrinology and Metabolism,2014,(04):214.[doi:10.3760/cma.j.issn.1673-4157.2014.03.020]
[2]陈堃,陈国芳,郑仁东,等.碳酸锂对甲状腺功能和形态的影响[J].国际内分泌代谢杂志,2014,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2014.04.009]
Chen Kun,Chen Guofang,Zheng Rendong,et al.Effects of carbonate lithium therapy on morphology and function of thyroid gland[J].International Journal of Endocrinology and Metabolism,2014,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2014.04.009]
[3]贾媛媛,陈莉丽.Th17细胞与Graves病及桥本甲状腺炎[J].国际内分泌代谢杂志,2014,(05):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
Jia Yuanyuan,Chen Lili.Relationship between Th17 cells and Graves' disease,Hashimoto's thyroiditis[J].International Journal of Endocrinology and Metabolism,2014,(04):344.[doi:10.3760/cma.j.issn.1673-4157.2014.05.016]
[4]房方,卫红艳,王坤玲,等.硒治疗自身免疫性甲状腺疾病的荟萃分析[J].国际内分泌代谢杂志,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
Fang Fang,Wei Hongyan,Wang Kunling,et al.A meta-analysis of selenium in the treatment of autoimmune thyroid diseases[J].International Journal of Endocrinology and Metabolism,2016,36(04):247.[doi:10.3760/cma.j.issn.1673-4157.2016.04.09]
[5]郑仁东,刘超.白细胞介素-6与甲状腺疾病[J].国际内分泌代谢杂志,2016,36(05):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
Zheng Rendong,Liu Chao.Interleukin-6 and thyroid disease[J].International Journal of Endocrinology and Metabolism,2016,36(04):352.[doi:10.3760/cma.j.issn.1673-4157.2016.05.18]
[6]郑慧娟,魏璠,魏军平.自噬与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2017,37(01):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
Zheng Huijuan,Wei Fan,Wei Junping..Autophagy and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2017,37(04):17.[doi:10.3760/cma.j.issn.1673-4157.2017.01.05]
[7]黄慧 胡欣 徐一娇 刘超.利妥昔单克隆抗体治疗Graves病的作用机制[J].国际内分泌代谢杂志,2018,38(02):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
Huang Hui,Hu Xin,Xu Yijiao,et al.Mechanism of rituximab in the treatment of Graves' disease[J].International Journal of Endocrinology and Metabolism,2018,38(04):121.[doi:10.3760/cma.j.issn.1673-4157.2018.02.013]
[8]苏亚峰 相萍萍 陈国芳 刘超.碘治疗Graves病的研究进展[J].国际内分泌代谢杂志,2019,39(01):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
Su Yafeng,Xiang Pingping,Chen Guofang,et al.Research progress of iodine in treating Graves' disease[J].International Journal of Endocrinology and Metabolism,2019,39(04):21.[doi:10.3760/cma.j.issn.1673-4157.2019.01.005]
[9]赫晓晴 单忠艳.肠道菌群与自身免疫性甲状腺疾病[J].国际内分泌代谢杂志,2020,40(03):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
He Xiaoqing,Shan Zhongyan.Gut microbiota and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2020,40(04):179.[doi:10.3760/cma.j.issn.1673-4157.2020.03.008]
[10]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(04):5.[doi:10.3760/cma.j.cn121383-20200608-06021]